Vera Therapeutics (VERA) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.30

Estimate

-$1.62

Surprise

+19.7%

Revenue (period 2026-09-30)

$10.3M

Score today

5.3/10

Revenue source: xbrl.

Vera Therapeutics (VERA) reported a narrower loss than forecast — adjusted EPS of -$1.30 against the -$1.62 estimate (a 19.7% beat on a still-unprofitable quarter).

• Vera Therapeutics Announces Inducement Grants for New Employees — fiscal.ai, 2026-11-06
• Wedbush Lowers Price Target on Vera Therapeutics to $29 — fiscal.ai, 2026-11-06
• Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $29 — benzinga, 2026-11-06

TrendMatrix currently rates VERA Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +19.7% surprise compares with a -2.1% four-quarter average. Next scheduled report: 2027-02-25.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$29.79

Price target

$64.19

Stop

$27.70

Upside to target

+115.5%

Reward-to-risk

9.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.15B

P/E (fwd)

-7.2

52-week range

$23.86–$56.05

Off 52-week high

46.9%

RSI (14)

53

Volume vs avg

1.27×

Score today

5.3/10